Emergent Biosolutions Inc (NYSE:EBS)’s traded shares stood at 0.87 million during the last session, with the company’s beta value hitting 1.60. At the close of trading, the stock’s price was $9.88, to imply a decrease of -0.90% or -$0.09 in intraday trading. The EBS share’s 52-week high remains $15.10, putting it -52.83% down since that peak but still an impressive 85.63% since price per share fell to its 52-week low of $1.42. The company has a valuation of $535.34M, with an average of 0.98 million shares in intraday trading volume over the past 10 days and average of 1.26 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Emergent Biosolutions Inc (EBS), translating to a mean rating of 2.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give EBS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.5.
Emergent Biosolutions Inc (NYSE:EBS) trade information
After registering a -0.90% downside in the last session, Emergent Biosolutions Inc (EBS) has traded red over the past five days. The 5-day price performance for the stock is 0.00%, and 11.39% over 30 days. With these gigs, the year-to-date price performance is 3.35%. Short interest in Emergent Biosolutions Inc (NYSE:EBS) saw shorts transact 7.13 million shares and set a 6.61 days time to cover.
The extremes give us $38 and $65 for target low and target high price respectively. As such, EBS has been trading -557.89% off suggested target high and -284.62% from its likely low.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Looking at statistics comparing Emergent Biosolutions Inc share performance against respective industry, we note that the company has outperformed competitors. Emergent Biosolutions Inc (EBS) shares are -13.56% down over the last 6 months, with its year-to-date growth rate higher than industry average at 89.89% against 16.60%. The rating firms project that company’s revenue will grow 5.18% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 254.67M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 279M.Earnings reports from the last fiscal year show that sales brought in 276.6M and 300.4M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -7.93% before dropping -7.12% in the following quarter.
EBS Dividends
Emergent Biosolutions Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Emergent Biosolutions Inc insiders hold 2.10% of total outstanding shares, with institutional holders owning 59.68% of the shares at 60.96% float percentage. In total, 59.68% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 3.84 million shares (or 7.3551% of shares), all amounting to roughly $26.18 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 3.67 million shares, or about 7.0234% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $25.0 million.
We also have Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF and Avantis U.S. Small Cap Value ETF as the top two Mutual Funds with the largest holdings of the Emergent Biosolutions Inc (EBS) shares. Going by data provided on Aug 31, 2024 , Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF holds roughly 2.36 shares. This is just over 4.36% of the total shares, with a market valuation of $23.32 million. Data from the same date shows that the other fund manager holds a little less at 1.68, or 3.10% of the shares, all valued at about 16.6 million.
